Conference Coverage

Elective CRC resections increase with universal insurance


 

FROM SSO 2016

References

Relative to controls, the adjusted probability that a patient with colorectal cancer in Massachusetts would have emergent surgery after admission declined by 6.1% (P = .014) and the probability that he or she would have elective resection increased by 7.8% (P = .005).

An analysis of the odds ratio of resection during admission, adjusted for age, race, presentation with metastatic disease, hospital type, and secular trends, showed that prior to reform uninsured patients in both Massachusetts and control states were significantly less likely than privately insured patients to have resections (odds ratio, 0.42 in Mass.; 0.45 in control states).

However, after the implementation of reform the gap between previously uninsured and privately insured in Massachusetts narrowed (OR, 0.63) but remained the same in control states (OR, 0.44).

Dr. Loehrer acknowledged in an interview that Massachusetts differs from other states in some regards, including in concentrations of health providers and in requirements for insurance coverage that were in place even before the 2006 reforms, but is optimistic that improvements in colorectal cancer care can occur in states that have embraced the Affordable Care Act.

“There are a lot of services that were available and we had high colonoscopy rates prior to all of this, but that said, the mechanism is exactly the same, there are still vulnerable populations, and at this point I think it’s hopeful and promising that we will see similar results in other states,” he said.

Pages

Recommended Reading

Labeled peptide bound the claudin-1 target in colorectal cancer models
MDedge Hematology and Oncology
Study backed familial component of advanced adenoma risk
MDedge Hematology and Oncology
Common medications linked to better survival in pancreatic cancer
MDedge Hematology and Oncology
Neurotoxicity tempers case for oxaliplatin in older adults with colorectal cancer
MDedge Hematology and Oncology
New GI therapies bring hope after much frustration
MDedge Hematology and Oncology
Muscle loss during chemotherapy predicts poor survival in metastatic colorectal cancer
MDedge Hematology and Oncology
SIRT plus FOLFOX chemo for mCRC improved progression-free survival in liver only
MDedge Hematology and Oncology
TAMIS for rectal cancer holds its own vs. TEM
MDedge Hematology and Oncology
Thrombocytopenia signals multiorgan system failure in acute liver failure
MDedge Hematology and Oncology
No HPV DNA detected in esophageal cancer tumors
MDedge Hematology and Oncology